Cargando…
Switching Between Epoetins: A Practice in Support of Biosimilar Use
BACKGROUND: The acceptability of switching between reference drugs and their biosimilars is often disputed. It is unclear whether this concern is specific to the use of biosimilars or is relevant to the practice of switching between any biological drugs. OBJECTIVE: The objective of this study was to...
Autores principales: | D’Amore, Carmen, Da Cas, Roberto, Rossi, Mariangela, Traversa, Giuseppe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4746226/ https://www.ncbi.nlm.nih.gov/pubmed/26728875 http://dx.doi.org/10.1007/s40259-015-0155-0 |
Ejemplares similares
-
Comparative Safety of Originator and Biosimilar Epoetin Alfa Drugs: An Observational Prospective Multicenter Study
por: Stoppa, Giovanna, et al.
Publicado: (2018) -
Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study
por: Belleudi, Valeria, et al.
Publicado: (2019) -
Quality of Original and Biosimilar Epoetin Products
por: Brinks, Vera, et al.
Publicado: (2010) -
Safety of switching between rituximab biosimilars in onco-hematology
por: Urru, Silvana A. M., et al.
Publicado: (2021) -
Biosimilar epoetin for the management of chemotherapy-induced anemia in elderly patients
por: Kurtz, Jean-Emmanuel, et al.
Publicado: (2016)